| pubmed-article:2150740 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2150740 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:2150740 | lifeskim:mentions | umls-concept:C0034493 | lld:lifeskim |
| pubmed-article:2150740 | lifeskim:mentions | umls-concept:C0015350 | lld:lifeskim |
| pubmed-article:2150740 | lifeskim:mentions | umls-concept:C0225369 | lld:lifeskim |
| pubmed-article:2150740 | lifeskim:mentions | umls-concept:C0224522 | lld:lifeskim |
| pubmed-article:2150740 | lifeskim:mentions | umls-concept:C0025519 | lld:lifeskim |
| pubmed-article:2150740 | lifeskim:mentions | umls-concept:C0521339 | lld:lifeskim |
| pubmed-article:2150740 | lifeskim:mentions | umls-concept:C0003211 | lld:lifeskim |
| pubmed-article:2150740 | lifeskim:mentions | umls-concept:C0059865 | lld:lifeskim |
| pubmed-article:2150740 | lifeskim:mentions | umls-concept:C2246343 | lld:lifeskim |
| pubmed-article:2150740 | lifeskim:mentions | umls-concept:C1709059 | lld:lifeskim |
| pubmed-article:2150740 | pubmed:issue | 3-4 | lld:pubmed |
| pubmed-article:2150740 | pubmed:dateCreated | 1991-5-14 | lld:pubmed |
| pubmed-article:2150740 | pubmed:abstractText | Cultures of human rheumatoid synovial cells and rabbit articular chondrocytes were exposed to various concentrations of Etodolac (from 0.01 to 10 micrograms/ml) in presence or absence of 500 pg/ml (5 U/ml) human recombinant Interleukin-1 beta (IL-1 beta). Incubation of chondrocytes with Etodolac for 24 h did not alter collagen biosynthesis. In contrast, 1 micrograms/ml Etodolac caused a 20% increase of collagen production in synoviocytes. Addition of Etodolac in combination with IL-1 could partially suppress the inhibitory effect exerted by the cytokine on both cell types. Four-day exposure of chondrocytes to 0.1 and 1 micrograms/ml Etodolac led to an increased accumulation of collagen in the cell layer compartment. However, this treatment could not prevent the inhibitory effect of IL-1 on this collagen fraction. Treatment of synoviocytes for eight days with the same concentrations of Etodolac did not modify their collagen production but suppressed totally the inhibitory effect of IL-1. These data show that Etodolac is able to augment chondrocyte metabolism during a long term treatment. Moreover, under certain conditions, this drug can reduce or even suppress the IL-1-induced inhibition of collagen biosynthesis, a process that may take a part in the connective tissue alterations associated with osteoarticular diseases such as rheumatoid arthritis and osteoarthritis. | lld:pubmed |
| pubmed-article:2150740 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2150740 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2150740 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2150740 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2150740 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2150740 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2150740 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2150740 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2150740 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2150740 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:2150740 | pubmed:issn | 0065-4299 | lld:pubmed |
| pubmed-article:2150740 | pubmed:author | pubmed-author:PujolJ PJP | lld:pubmed |
| pubmed-article:2150740 | pubmed:author | pubmed-author:LoyauGG | lld:pubmed |
| pubmed-article:2150740 | pubmed:author | pubmed-author:MauvielAA | lld:pubmed |
| pubmed-article:2150740 | pubmed:author | pubmed-author:RediniFF | lld:pubmed |
| pubmed-article:2150740 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2150740 | pubmed:volume | 31 | lld:pubmed |
| pubmed-article:2150740 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2150740 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2150740 | pubmed:pagination | 345-52 | lld:pubmed |
| pubmed-article:2150740 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:2150740 | pubmed:meshHeading | pubmed-meshheading:2150740-... | lld:pubmed |
| pubmed-article:2150740 | pubmed:meshHeading | pubmed-meshheading:2150740-... | lld:pubmed |
| pubmed-article:2150740 | pubmed:meshHeading | pubmed-meshheading:2150740-... | lld:pubmed |
| pubmed-article:2150740 | pubmed:meshHeading | pubmed-meshheading:2150740-... | lld:pubmed |
| pubmed-article:2150740 | pubmed:meshHeading | pubmed-meshheading:2150740-... | lld:pubmed |
| pubmed-article:2150740 | pubmed:meshHeading | pubmed-meshheading:2150740-... | lld:pubmed |
| pubmed-article:2150740 | pubmed:meshHeading | pubmed-meshheading:2150740-... | lld:pubmed |
| pubmed-article:2150740 | pubmed:meshHeading | pubmed-meshheading:2150740-... | lld:pubmed |
| pubmed-article:2150740 | pubmed:meshHeading | pubmed-meshheading:2150740-... | lld:pubmed |
| pubmed-article:2150740 | pubmed:meshHeading | pubmed-meshheading:2150740-... | lld:pubmed |
| pubmed-article:2150740 | pubmed:meshHeading | pubmed-meshheading:2150740-... | lld:pubmed |
| pubmed-article:2150740 | pubmed:meshHeading | pubmed-meshheading:2150740-... | lld:pubmed |
| pubmed-article:2150740 | pubmed:meshHeading | pubmed-meshheading:2150740-... | lld:pubmed |
| pubmed-article:2150740 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:2150740 | pubmed:articleTitle | Modulation of extracellular matrix metabolism in rabbit articular chondrocytes and human rheumatoid synovial cells by the non-steroidal anti-inflammatory drug etodolac. I: Collagen synthesis. | lld:pubmed |
| pubmed-article:2150740 | pubmed:affiliation | Laboratoire de Biochimie du Tissu Conjonctif, C.H.U. Côte de Nacre, Caen, France. | lld:pubmed |
| pubmed-article:2150740 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2150740 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
